Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma

Bonte, J; P, Ide; Billiet, G.; Wynants, P

doi:10.1016/s0090-8258(81)80003-0

Cited by 58 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In postmenopausal women, Ferrazzi (14) reported a partial agonist effect in the majority of a group of postmenopausal women while Estevez (15) saw mainly anti-oestrogenic or no effects. Bonte (16) reported oestrogenic effects on the vagina but anti-oestrogenic effects on the endometrium in the same patients.…”

Section: Is Tamoxifen An Oestrogen Antagonist?mentioning

confidence: 93%

The biology and physiology of ‘Nolvadex’ (tamoxifen) in the treatment of breast cancer

Patterson¹,

Furr²,

Wakeling³

et al. 1982

Breast Cancer Res Tr

View full text Add to dashboard Cite

SummaryAfter more than a quarter of a million patient years experience with tamoxifen in the clinic, it is perhaps appropriate to re-examine the working hypothesis for the activity of this drug. This hypothesis states that tamoxifen is an anti-oestrogen which exerts its anti-tumour activity by competing for and binding to cytoplasmic oestrogen receptor protein in the tumour.The evidence that tamoxifen is an anti-oestrogen in animals and man is seen to vary from species to species and between target organs within a species. The balance of the evidence supports the conclusion that this drug acts as an oestrogen antagonist in man.If the activity of this drug were confined to an effect mediated by the oestrogen receptor (ER), there should be a clear correlation between the anti-tumour effect of tamoxifen and the presence of ER. The clinical and pre-clinical data are reviewed. Whilst the majority of the evidence points to an effect in advanced breast cancer mediated through the ER, there are data that show the correlation is not absolute. The data are examined and the evidence for non-receptor mediated anti-tumour activity is reviewed.We conclude that whilst the majority of the activity of tamoxifen is that of an anti-oestrogen mediated through the ER, compelling evidence exists that this may not be its only anti-tumour activity at normal clinical doses. These findings might explain tamoxifen's activity in some ER negative tumours.

show abstract

Section: Is Tamoxifen An Oestrogen Antagonist?mentioning

confidence: 93%

The biology and physiology of ‘Nolvadex’ (tamoxifen) in the treatment of breast cancer

Patterson¹,

Furr²,

Wakeling³

et al. 1982

Breast Cancer Res Tr

View full text Add to dashboard Cite

show abstract

“…Endometrial cancer and thrombosis-related phenomena are well-known side-effects of this drug, however, because of its ample use it is important to be aware of other uncommon toxicities. Although skin changes caused by tamoxifen were reported in 19% of tamoxifen treated patients [15], and also published medical literatureidentified occasional reports of skin reactions (urticaria) in patients receiving tamoxifen [16-18], the development of purpuric vasculitis due to tamoxifen is extremely unsual, since only two cases of purpuric vasculits have been reported in the literature [19,20]. In the first case [19], also a mild elevation of aspartate aminotransferase level was documented, but neither a clear cholestatic damage or arthritis; a clear drug-relation was documented, since vasculitis disappeared after tamoxifen withdrawal, and reappeared when this drug was newly indicated.…”

Section: Discussionmentioning

confidence: 99%

Tamoxifen-associated vasculitis in a breast cancer patient

et al. 2007

View full text Add to dashboard Cite

show abstract

“…10 The pooled response rate of tamoxifen of several small phase II trials with a total of 257 patients was 22%. 6 In second-line therapy, approximately half of the patients who previously responded to progestagen therapy did respond to tamoxifen (response rates of 53% and 57%), 17,18 this in contrast to none of the patients who were refractory to progesterone. 19,20 In hormone-naive patients, responses to tamoxifen were observed in 10% and 21% of the patients.…”

Section: Hormone Therapymentioning

confidence: 99%

Management of Recurrent Endometrioid Endometrial Carcinoma: An Overview

Wijk

Burg

Burger

et al. 2009

Int J Gynecol Cancer

View full text Add to dashboard Cite

In this paper, an overview of the literature on the management of recurrent endometrial cancer is presented, focusing on patients with histopathologic endometrioid type of tumors. The different treatment modalities are described, and a management recommendation scheme is presented. Indications for surgical treatment depend on resectability, site and size of the tumor, and performance status of the patient. Indications for radiotherapy depend on the site of the recurrence and also on the initial therapy received. When considering systemic treatment for patients with recurrent endometrial cancer, it is important to take into account the general health status and condition of the patient as well as which prior therapy the patient has received. The treatments of choice for patients with hormone-sensitive tumors (positive receptor levels, low-grade tumors, and long disease-free interval) are progestagens as first-line treatment and tamoxifen as second-line treatment. Patients with high-grade tumors, negative hormone receptor levels, and short treatment-free interval are best treated with chemotherapy. Paclitaxel, doxorubicin, and cisplatin are the most active combination therapy for these patients but with significant toxicity. In phase II studies, the combination therapy with paclitaxel and carboplatin seems to be as effective but less toxic and can be administered in outpatient clinic. The literature on the management of patients with recurrent endometrial cancer is discussed in detail. The different sites of recurrent disease (ie, local, regional, and/or distant) are evaluated separately; management recommendations are proposed, and alternative approaches are given.

show abstract

Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma

Cited by 58 publications

References 14 publications

The biology and physiology of ‘Nolvadex’ (tamoxifen) in the treatment of breast cancer

The biology and physiology of ‘Nolvadex’ (tamoxifen) in the treatment of breast cancer

Tamoxifen-associated vasculitis in a breast cancer patient

Management of Recurrent Endometrioid Endometrial Carcinoma: An Overview

Contact Info

Product

Resources

About